Trials / Conditions / Refractory Anaplastic Large Cell Lymphoma

Refractory Anaplastic Large Cell Lymphoma

11 registered clinical trials studyying Refractory Anaplastic Large Cell Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas NCT04774068	Walter Hanel	Phase 1
Completed	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refr NCT04074746	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625	National Cancer Institute (NCI)	Phase 2
Terminated	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT03075553	Mayo Clinic	Phase 2
Recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820	Mayo Clinic	Phase 1
Terminated	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL NCT02572453	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409	Mayo Clinic	N/A
Completed	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Periph NCT01590732	M.D. Anderson Cancer Center	Phase 1
Completed	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770	Children's Oncology Group	Phase 1 / Phase 2